Skip to main navigation
  • Careers
  • Contact Us
  • About Us
    • Corporate Governance
    • Executive Leadership
    • Board of Directors
    • Sustainability
    • Ethics & Integrity
  • News & Events
    • Press Releases
    • Events & Presentations
  • Investors
    • Investor Kit
    • Stock Information
    • Financials
    • SEC Filings
  • Therapeutic Areas
    • Cardiopulmonary
    • Difficult-to-Treat Depression
    • Drug-Resistant Epilepsy

    code
    General

    Jette Nygaard-Andersen Joins LivaNova Board as a New Director

    • Read more about Jette Nygaard-Andersen Joins LivaNova Board as a New Director

    LivaNova Appoints Anne Liddy as Chief Legal Officer

    • Read more about LivaNova Appoints Anne Liddy as Chief Legal Officer

    LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit

    • Read more about LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit

    LivaNova to Present at Goldman Sachs Global Healthcare Conference in June

    • Read more about LivaNova to Present at Goldman Sachs Global Healthcare Conference in June

    Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea

    • Read more about Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea

    LivaNova to Announce First-Quarter 2026 Results

    • Read more about LivaNova to Announce First-Quarter 2026 Results

    LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea

    • Read more about LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea

    LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results

    • Read more about LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results

    LivaNova to Present at J.P. Morgan Healthcare Conference in January

    • Read more about LivaNova to Present at J.P. Morgan Healthcare Conference in January

    LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting

    • Read more about LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting

    Pagination

    • Page 1
    • Next page ››
    Subscribe to General

    Our Company

    • About Us
    • News

    Therapeutic Areas

    • Cardiopulmonary
    • Drug-Resistant Epilepsy
    • Difficult-to-Treat Depression

    Contact Us

    • Customer Service
    • Commercial Sponsorship
    • Donations and Grants
    • Investigator-Initiated Research

    Transparency

    • Modern Slavery Statement
    • Carbon Reduction Plan
    • Conflict Minerals
    • © 2026 LivaNova PLC

    • Careers
    • Investors
    • Terms of Use
    • Privacy Policy
    • Washington Nevada Consumer Health Data
    • Cybersecurity
    • Patents
    • Cookie Policy
    • Cookie Settings

    LivaNova PLC - Registered in England and Wales - Registered No. 09451374 - 20 Eastbourne Terrace, London, W2 6LG, United Kingdom

    Top